Sarepta Therapeutics, Inc. SRPT Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sarepta Therapeutics, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sarepta Therapeutics, Inc.'s accounts receivable?
- Sarepta Therapeutics, Inc. (SRPT) reported accounts receivable of $394.82M in Q1 2026.
- How has Sarepta Therapeutics, Inc.'s accounts receivable changed year-over-year?
- Sarepta Therapeutics, Inc.'s accounts receivable decreased by 40.1% year-over-year, from $659.37M to $394.82M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s accounts receivable?
- Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s accounts receivable has grown at a 31.5% compound annual growth rate (CAGR), from $101.34M to $398.23M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.